Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
NVIDIA Resumes China AI Chip Production Amid $1 Trillion Revenue Forecast 
Elliott Investment Management Takes Multibillion-Dollar Stake in Synopsys 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Micron Technology Beats Q2 Earnings Estimates, Issues Strong AI-Driven Outlook 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Anthropic Sues Pentagon Over AI Blacklist, Citing Free Speech Violations 
Trump White House Unveils National AI Policy Framework for Congress 
Costco Faces Class Action Lawsuit Over Tariff Refunds as Supreme Court Strikes Down Trump's IEEPA Tariffs 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
xAI Faces Federal Lawsuit Over Grok AI-Generated Child Sexual Abuse Material 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Estée Lauder Sues Jo Malone Over Trademark Dispute Involving Zara 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Super Micro Computer Shares Plunge After Co-Founder Charged in AI Chip Smuggling Case 
ICE Arrests Colombian Journalist in Tennessee, Trump Administration Says She Will Receive Due Process 
A federal jury in California has ordered Apple to pay $634 million to Masimo after finding that features in the Apple Watch infringed on the medical-technology company’s blood-oxygen monitoring patent. The decision concludes that Apple’s workout mode and heart rate notification tools violated Masimo’s intellectual property, according to a spokesperson for the company.
Apple says it strongly disagrees with the ruling and will appeal. The tech giant noted that Masimo has pursued more than two dozen patent claims against Apple over the past six years, most of which were deemed invalid. Apple also stressed that the patent at the center of this case expired in 2022 and applies to older, traditional patient-monitoring technology.
Masimo celebrated the verdict, calling it a major step toward protecting its long-standing innovations. The lawsuit is part of a broader legal battle that has intensified tensions between the two companies. Masimo has accused Apple of poaching its employees and misappropriating its pulse oximetry technology for use in Apple Watch models.
The ongoing dispute previously contributed to a U.S. International Trade Commission (ITC) decision that temporarily blocked imports of the Apple Watch Series 9 and Ultra 2 in 2023. The ban was based on findings that Apple’s blood-oxygen technology infringed Masimo’s patents. To sidestep the import halt, Apple removed the pulse-oximetry feature from affected watches and later released an updated version approved by U.S. Customs and Border Protection.
However, the ITC announced it will reassess whether Apple’s updated models should still face restrictions. Masimo has also taken legal action against Customs over its approval decision, while Apple continues to challenge the ITC’s original import ruling in federal court.
This long-running dispute has seen mixed results on both sides. A separate trade-secret trial in California ended in a mistrial in 2023, and Apple won only $250 in a Delaware case claiming Masimo’s devices infringed two Apple design patents.
